$PMCB ~ "All of these factors are important parameters in assessing treatment outcome in clinical trials of patients with pancreatic cancer undergoing neoadjuvant therapy (used to shrink a tumor prior to additional treatment such as surgery) and the divergence of these matters among pancreatic cancer clinical trials makes interpretation of trial results and comparisons among trials quite difficult."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.